期刊文献+

Imatinib mesylate in clinically suspected gastric stromal tumors 被引量:4

Imatinib mesylate in clinically suspected gastric stromal tumors
下载PDF
导出
摘要 Gastrointestinal stromal tumors (GISTs) occur most frequently in the stomach.Diagnosis of gastric GIST is not always clear before surgery.Flexible endoscopy may suggest the nature of the lesion (a bulky tumor with preserved mucosa); however,biopsy is rarely diagnostic.Therefore,diagnostic medication with safe drugs may provide a feasible way under such conditions after an informed consent is obtained.Based on the excellent efficacy of imatinib mesylate (IM) in the treatment of GIST,we successfully applied it in the diagnostic medication of two patients with clinically suspected gastric stromal tumors.In conclusion,the diagnostic medication with IM can be an alternative option for patients with suspected GIST that can not be confirmed pathologically. Gastrointestinal stromal tumors (GISTs) occur most frequently in the stomach.Diagnosis of gastric GIST is not always clear before surgery.Flexible endoscopy may suggest the nature of the lesion (a bulky tumor with preserved mucosa); however,biopsy is rarely diagnostic.Therefore,diagnostic medication with safe drugs may provide a feasible way under such conditions after an informed consent is obtained.Based on the excellent efficacy of imatinib mesylate (IM) in the treatment of GIST,we successfully applied it in the diagnostic medication of two patients with clinically suspected gastric stromal tumors.In conclusion,the diagnostic medication with IM can be an alternative option for patients with suspected GIST that can not be confirmed pathologically.
出处 《Chinese Journal of Cancer Research》 SCIE CAS CSCD 2013年第5期600-602,共3页 中国癌症研究(英文版)
基金 supported by WU JIEPING Medical Foundation(No.WJP-320.6700.09010)
关键词 Gastrointestinal stromal tumors (GISTs) imatinib mesylate (IM) magnetic resonance imaging (MRI) Gastrointestinal stromal tumors (GISTs) imatinib mesylate (IM) magnetic resonance imaging (MRI)
  • 相关文献

参考文献5

  • 1Fletcher CD, Berman JJ, Corless C, et al. Diagnosis of gastrointestinal stromal tumors: A consensus approach. Hum Patho12002;33:459-65.
  • 2Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N EnglJ Med 2002;347:472-80.
  • 3Eisenberg BL, Harris J, Blanke CD, et al. Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): early results of RTOG 0132/ ACRIN 6665. J Surg Onco12009;99:42-7.
  • 4Choi H, Charnsangavej C, Faria SC, et al. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Onco12007;25:1753-9.
  • 5Tang L, Zhang XP, Sun YS, et al. Gastrointestinal stromal tumors treated with imatinib mesylate: apparent diffusion coefficient in the evaluation of therapy response in patients. Radiology 2011;258:729-38.

同被引文献11

引证文献4

二级引证文献27

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部